Clinical Trials & Treatment Updates

Find out more about clinical trials and the companies that instigate by following the links below;

Cyclo Therapeutics to present clinical and drug development program for Trappsol® Cyclo™, at WORLDSymposium 2021

January 26, 2021

a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of Neurodegenerative Diseases, including their lead candidate (Trappsol® Cyclo™) in the treatment of Niemann-Pick Disease Type C (NPC)

IntraBio New Drug Application Approved by the FDA for the Treatment of NPC

February 16, 2019

This approval allows IntraBio to begin with the trial at U.S. clinical sites. In addition to the U.S. centers, IntraBio intends to commence the study in European countries, including the United Kingdom, Germany, Slovakia, and Spain

Orphazyme reports positive results from full data set of Phase II/III arimoclomol trial in Niemann-Pick disease Type C (NPC)

January 30, 2019

Primary endpoint shows 74% reduction in disease progression after 12 months compared to placebo control

CTD Announces Presentation at Upcoming Conference on Lysosomal Storage Diseases

January 11, 2019

CTD Holdings: Annual conference offers opportunities for academic researchers and industry representatives to exchange information on novel therapeutic interventions...

 
  • Facebook
  • Instagram
  • Twitter
  • LinkedIn

Subscribe to Our Site

©2021 by Australian NPC Disease Foundation Inc.

Australian NPC Disease Foundation Inc is registered with the Australian Tax Office as an Income Tax Exempt Charity. All donations over $2 are tax deductible.